Wealthfront Advisers LLC Lowers Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Wealthfront Advisers LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 94.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,195 shares of the medical device company's stock after selling 19,083 shares during the quarter. Wealthfront Advisers LLC's holdings in DexCom were worth $93,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Forvis Mazars Wealth Advisors LLC grew its holdings in DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after acquiring an additional 118 shares during the last quarter. Principal Securities Inc. grew its holdings in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after acquiring an additional 135 shares during the last quarter. Larson Financial Group LLC grew its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the last quarter. GPS Wealth Strategies Group LLC grew its holdings in DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company's stock worth $123,000 after acquiring an additional 185 shares during the last quarter. Finally, Peterson Wealth Services grew its holdings in DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company's stock worth $236,000 after acquiring an additional 201 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Remove Ads

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of research reports. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Citigroup boosted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.82.

DexCom Stock Performance

NASDAQ DXCM traded down $1.31 during trading on Friday, hitting $73.80. 5,526,457 shares of the company's stock traded hands, compared to its average volume of 3,906,016. The stock has a market capitalization of $28.84 billion, a price-to-earnings ratio of 51.61, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The business has a 50 day moving average of $83.41 and a 200-day moving average of $76.92.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.